Licensing

medicine

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About TwinStrand Biosciences

TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing™ technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.TwinStrandBio.com.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Source Article

Read More
medicine

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences – Press Release

CAMBRIDGE, Mass.–(Business Wire)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About TwinStrand Biosciences

TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing™ technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.TwinStrandBio.com.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Lee-Ann Murphy, 617-245-3077

[email protected]

Abigail Alderman, 781-534-3210

[email protected]

// Load the SDK Asynchronously (function(d){ var js, id = 'facebook-jssdk', ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) {return;} js = d.createElement('script'); js.id = id; js.async = true; js.src = "http://connect.facebook.net/en_US/all.js"; ref.parentNode.insertBefore(js, ref); })(document); })();

Source Article

Read More
health

VitalHub Continues to Increase NHS UK Presence with Additional Regional Licensing Deal of Synopsis Products

TORONTO, Oct. 28, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the licensing of newly-acquired subsidiary Intouch With Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis iQ, to Northumbria Healthcare NHS Foundation Trust (“Northumbria” or the “Trust”).

Northumbria Healthcare NHS Foundation Trust has licensed VitalHub subsidiary Intouch’s digital pre-operative solution platform, Synopsis iQ, as the Trust launches a new digital pre-operative assessment (POA) pathway that will improve demand and capacity planning and resource utilization, helping to fill last-minute surgery slots and reducing the number of face-to-face appointments the department processes.

The Synopsis solution will enable Northumbria to meet a number of Trust targets, such as reducing the face-to-face appointments, which has become a much-needed requirement in the pandemic climate. Synopsis will provide the Trust with tools to afford patients with an improved experience leading up to surgery, affecting both the delivery and quality of care provided.

The project is part of the Trust’s drive to create a more efficient operating room booking pathway by creating a pool of ‘pre-op ready’ patients’ consultants can use to create operating room lists and fill last-minute surgery slots. As part of the project, patients waiting for surgery will also be able to complete their POA health questionnaire at home via a secure link on the Trust’s website. Results are then sent to the Trust’s pre-operative assessment department where staff can triage and swim-lane patients into the correct fitness and readiness categories.

The Trust identified a considerable burden on pre-op assessment departments, facing high volumes of last-minute requests for patient appointments, resulting in operating time delays and resource inefficiencies. Prior to the COVID-19 pandemic, the Trust established a target to reduce the number of face-to-face appointments patients had to attend, creating a need for a pre-op pathway solution, and has selected Synopsis iQ and Synopsis Home as their solutions of choice to enable the progression of this target.

Digitizing the pre-operative assessment process will also allow consultants and anaesthetists to access full patient notes from any of the Trust’s four hospital sites. The project will be rolled out across North Tyneside General Hospital, Northumbria Specialist Emergency Care Hospital, Hexham General Hospital and Wansbeck General Hospital, giving staff across all four hospitals secure access to patient records and a real-time view of each patient’s status through the pre-operative pathway.

Northumbria Healthcare NHS Foundation Trust is a regional healthcare network that provides a range of health and care services to support more than 500,000 people living in Northumberland and North Tyneside. The Trust delivers care from 11 sites, including their emergency care hospital, general and community hospitals, outpatient and diagnostic centers, an elderly care unit and an integrated health and social care facility. The Trust admitted over 116,000 patients and handled over 368,000 outpatient appointments in the 2017/18 period.

“We are seeing an aggressive uptick in awareness and interest in the Synopsis suite of products,” said Dan Matlow, CEO of VitalHub Corp. “With this contract, we add another

Read More